Role of MALDI-MSI in combination with 3D tissue models for early stage efficacy and safety testing of drugs and toxicants. (1st December 2020)

• Record Type: Journal Article
• Authors: Spencer, Chloe E; Flint, Lucy E; Duckett, Catherine J; Cole, Laura M; Cross, Neil; Smith, David P; Clench, Malcolm R
• Is Part Of: Expert review of proteomics. Volume 17:Number 11/12(2020)
• Page Start: 827
• Page End: 841
• Publication Date: 2020-12-01
• Subjects: Mass spectrometry imaging (MSI) -- organoids -- GI tract; Proteins -- Biotechnology -- Periodicals; Proteomics -- Periodicals; 572.6
• DOI: 10.1080/14789450.2021.1876568
• Languages: English
• ISSNs: 1478-9450

Abstract

ABSTRACT: Introduction : Three-dimensional (3D) cell cultures have become increasingly important materials to investigate biological processes and drug efficacy and toxicity. The ability of 3D cultures to mimic the physiology of primary tissues and organs in the human body enables further insight into cellular behavior and is hence highly desirable in early-stage drug development. Analyzing the spatial distribution of drug compounds and endogenous molecules provides an insight into the efficacy of a drug whilst simultaneously giving information on biological responses. Areas Covered : In this review we will examine the main 3D cell culture systems employed and applications, which describe their integration with mass spectrometry imaging (MSI). Expert Opinion : MSI is a powerful technique that can map a vast range of molecules simultaneously in tissues without the addition of labels that can provide insights into the efficacy and safety of a new drug. The combination of MSI and 3D cell cultures has emerged as a promising tool in early-stage drug analysis. However, the most common administration route for pharmaceutical drugs is via oral delivery. The use of MSI in combination with models of the GI tract is an area that has been little explored to date, the reasons for this are discussed.